Patents by Inventor Hiroyuki Sonoda
Hiroyuki Sonoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958905Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.Type: GrantFiled: June 16, 2021Date of Patent: April 16, 2024Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20240066149Abstract: The invention provides a nucleic acid molecule comprising a gene encoding a fusion protein of a ligand and a protein having physiological activity, to be used for expressing the fusion protein in cells, tissue or the body. The invention further provides a nucleic acid molecule comprising the fusion protein-encoding gene, which is in the form of a plasmid, in a form encapsulated in a recombinant virus virion, or a form encapsulated in liposomes or lipid nanoparticles. The invention further relates to the use of a medicine which is a nucleic acid molecule comprising the fusion protein-encoding gene.Type: ApplicationFiled: January 11, 2022Publication date: February 29, 2024Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Masafumi Kinoshita, Shunsuke Iizuka, Atsushi Imakiire, Haruna Takagi, Hiroyuki Sonoda
-
Patent number: 11512135Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.Type: GrantFiled: August 25, 2017Date of Patent: November 29, 2022Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
-
Publication number: 20220064288Abstract: Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.Type: ApplicationFiled: November 19, 2021Publication date: March 3, 2022Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11248045Abstract: Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.Type: GrantFiled: June 24, 2016Date of Patent: February 15, 2022Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20210309754Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.Type: ApplicationFiled: June 16, 2021Publication date: October 7, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11130815Abstract: Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.Type: GrantFiled: June 24, 2016Date of Patent: September 28, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11111308Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: June 23, 2020Date of Patent: September 7, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20210269543Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: May 17, 2021Publication date: September 2, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11078293Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: June 23, 2020Date of Patent: August 3, 2021Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20210038739Abstract: [Problems] To provide a technique for efficiently incorporating an agent having to function in muscle tissue, which is not sufficiently incorporated into muscle tissue when administered in body, into muscle tissue, particularly muscle tissue composed of skeletal muscle or cardiac muscle. [Solution] A conjugate of an anti-human transferrin receptor antibody and an agent, wherein the agent is a biologically active agent that should function in muscle tissue, e.g., a lysosomal enzyme such as acid ?-glucosidase, ?-galactosidase A.Type: ApplicationFiled: February 5, 2019Publication date: February 11, 2021Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Kenichi Takahashi, Hiroyuki Sonoda
-
Publication number: 20200406845Abstract: Problem: To integrate portions of lamps and sensors with a bumper fascia, reduce the number of components and the number of man-hours for assembly, and easily assemble a vehicle exterior assembly to an outer surface of a vehicle body. Solution: In an exterior assembly 11 for being installed on a front surface of a vehicle body, head lamps 13 and fog lamps 14 that provide illumination in front of a vehicle and sensors 15 that collect information from in front of the vehicle are arranged in vertical rows on a bumper fascia 12. Lens portions 18 and 21 of the lamps 13 and 14 and antenna portions 24 of the sensors 15 are integrally formed with both right and left ends of the bumper fascia 12. Body portions 19 and 22 of the lamps 13 and 14 and case portions 25 of the sensors 15 are integrally formed in a separate molding step from that for the bumper fascia 12 and assembled to a back surface of the bumper fascia 12 as single components.Type: ApplicationFiled: March 13, 2019Publication date: December 31, 2020Inventor: Hiroyuki Sonoda
-
Patent number: 10876703Abstract: A light guide is configured to allow at least a portion of light incident on a light-incident surface to be emitted through a peripheral surface. The light guide includes a light guide portion extending in a lengthwise direction of the light guide and formed of a first material and a luminous portion extending in the lengthwise direction of the light guide along the light guide portion and formed of a second material. The second material has a haze value greater than a haze value of the first material.Type: GrantFiled: August 10, 2018Date of Patent: December 29, 2020Assignee: KOITO MANUFACTURING CO., LTD.Inventors: Asami Sakashita, Kazuyuki Ishikawa, Hiroaki Hara, Koki Matsui, Hiroyuki Sonoda
-
Publication number: 20200384061Abstract: The present invention provides a fusion protein of BDNF and an anti-human transferrin receptor antibody, in which in a heavy chain variable region of the antibody, (a) CDR1 includes an amino acid sequence of SEQ ID NO: 66 or SEQ ID NO: 67, (b) CDR2 includes an amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 includes an amino acid sequence of SEQ ID NO: 15 or SEQ ID NO: 16.Type: ApplicationFiled: December 26, 2017Publication date: December 10, 2020Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 10858640Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.Type: GrantFiled: April 28, 2017Date of Patent: December 8, 2020Assignee: JCR PHARMACEUTICALS CO., LTD.Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
-
Publication number: 20200317798Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: June 23, 2020Publication date: October 8, 2020Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 10759864Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: GrantFiled: December 26, 2017Date of Patent: September 1, 2020Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20190338043Abstract: Provided is an anti-human transferrin receptor antibody or an analog thereof, wherein in the heavy chain variable region of the antibody, (a) CDR1 comprises the amino acid sequence set forth as SEQ ID NO: 62 or SEQ ID NO: 63, (b) CDR2 comprises the amino acid sequence set forth as SEQ ID NO: 13 or SEQ ID NO: 14, and (c) CDR3 comprises the amino acid sequence set forth as SEQ ID NO: 15 or SEQ ID NO: 16, and an analogue thereof.Type: ApplicationFiled: December 26, 2017Publication date: November 7, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Publication number: 20190225700Abstract: Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.Type: ApplicationFiled: August 25, 2017Publication date: July 25, 2019Applicant: JCR Pharmaceuticals Co., Ltd.Inventors: Yuri Koshimura, Hiroyuki Sonoda, Miroslav Matev, Shinji Kakimoto, Tsuyoshi Fukui, Yukichi Hatano
-
Publication number: 20190049088Abstract: A light guide is configured to allow at least a portion of light incident on a light-incident surface to be emitted through a peripheral surface. The light guide includes a light guide portion extending in a lengthwise direction of the light guide and formed of a first material and a luminous portion extending in the lengthwise direction of the light guide along the light guide portion and formed of a second material. The second material has a haze value greater than a haze value of the first material.Type: ApplicationFiled: August 10, 2018Publication date: February 14, 2019Applicant: KOITO MANUFACTURING CO., LTD.Inventors: Asami SAKASHITA, Kazuyuki ISHIKAWA, Hiroaki HARA, Koki MATSUI, Hiroyuki SONODA